Upgrade to SI Premium - Free Trial

Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D'

November 9, 2017 9:56 AM
BMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $39.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles